Cybin Advances to Phase 3 Potential: Successful Enrollment Completion in CYB003 Phase 2 Study for Major Depressive Disorder Treatment
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. (NYSE:CYBN) has completed enrollment in its Phase 2 study of CYB003, a treatment for major depressive disorder. The company has reported no serious adverse events and a favorable safety profile. Cybin plans to scale the CYB003 program to a potential Phase 3 study in early 2024. The program is supported by a recently granted U.S. patent and the company anticipates potential Breakthrough Therapy designation, subject to FDA approval, in Q4 2023.
September 21, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has completed Phase 2 study for its major depressive disorder treatment, CYB003, and plans to initiate Phase 3 study in early 2024. The company also anticipates potential Breakthrough Therapy designation, subject to FDA approval.
The completion of Phase 2 study and the potential advancement to Phase 3 study for CYB003 indicates positive progress in Cybin's pipeline. This, along with the anticipation of potential Breakthrough Therapy designation, could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100